No products in the cart.
Mouse Monoclonal Anti-NFKB1 antibody (STJ99314)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-2000; ELISA 1:10000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-NFKB1 antibody.
Check alternative names for the antibodyExpand
|DKFZp686C01211 antibody|DNA binding factor KBF1 antibody|DNA binding factor KBF1 EBP1 antibody|DNA-binding factor KBF1 antibody|EBP 1 antibody|EBP-1 antibody|EBP1 antibody|KBF1 antibody|MGC54151 antibody|NF kappa B antibody|NF kappaB antibody|NF kappabeta antibody|NF kB1 antibody|NFkappaB antibody|NFKB 1 antibody|NFKB p105 antibody|NFKB p50 antibody|Nfkb1 antibody|NFKB1_HUMAN antibody|Nuclear factor kappa B DNA binding subunit antibody|Nuclear factor kappa-B, subunit 1 antibody|Nuclear factor NF kappa B p105 subunit antibody|Nuclear factor NF kappa B p50 subunit antibody|Nuclear factor NF-kappa-B p50 subunit antibody|Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody|Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody|Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody|p105 antibody|p50 antibody|p84/NF-kappa-B1 p98 antibody|Transcription factor NFKB1 antibody|Anti-NFkB p105 / p50 antibody [E381] (ab32360)
SCBT cat No: sc-1192|
|Catalogue No.|| |
Anti-NFKB1 antibody detects endogenous levels of NF-kappaB1 p105/p50 and does not cross-react with related proteins.
Recombinant human NF-kappaB1 p105/p50 protein.
|Recommended dilution|| |
WB 1:500-2000; ELISA 1:10000-20000
Anti-NFKB1 antibody was tube-contained in liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Anti-NFKB1 antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
DKFZp686C01211 antibody, DNA binding factor KBF1 antibody, DNA binding factor KBF1 EBP1 antibody, DNA-binding factor KBF1 antibody, EBP 1 antibody, EBP-1 antibody, EBP1 antibody, KBF1 antibody, MGC54151 antibody, NF kappa B antibody, NF kappaB antibody, NF kappabeta antibody, NF kB1 antibody, NFkappaB antibody, NFKB 1 antibody, NFKB p105 antibody, NFKB p50 antibody, Nfkb1 antibody, NFKB1_HUMAN antibody, Nuclear factor kappa B DNA binding subunit antibody, Nuclear factor kappa-B, subunit 1 antibody, Nuclear factor NF kappa B p105 subunit antibody, Nuclear factor NF kappa B p50 subunit antibody, Nuclear factor NF-kappa-B p50 subunit antibody, Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody, Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody, p105 antibody, p50 antibody, p84/NF-kappa-B1 p98 antibody, Transcription factor NFKB1 antibody
|Database links|| |
|Protein function|| |
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5′-GGRNNYYCC-3′, located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. .
|Involvement in disease|| |
Immunodeficiency, common variable, 12 (CVID12) [MIM:616576]: A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. . Note=The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Contains 7 ANK repeats. ; Contains 1 death domain. ; Contains 1 RHD (Rel-like) domain. The C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.; Glycine-rich region (GRR) appears to be a critical element in the generation of p50.
|Protein post-translational modifications|| |
While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing. .; Phosphorylation at ‘Ser-903’ and ‘Ser-907’ primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at ‘Ser-927’ and ‘Ser-932’ are required for BTRC/BTRCP-mediated proteolysis. .; Polyubiquitination seems to allow p105 processing. .; S-nitrosylation of Cys-61 affects DNA binding. .; The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur as an alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.
|Protein cellular localization|| |
Nucleus. Cytoplasm. Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).
AntibodyPlus can customize Anti-NFKB1 antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: